Navigation Links
It's in the genes: Study opens door to new treatment of the blues

A Florida State University scientist used a gene transfer technique to block the expression of a gene associated with clinical depression in a new study of mice that could lead to better treatment of human beings with this condition.

Carlos Bolanos, an assistant professor of psychology and neuroscience, was among a team of researchers that identified the role of a gene called Brain Derived Neurotrophic Factor (BDNF) in the development of social aversion. Mice treated with a transfer technique to block expression of the BDNF gene in a small area of the mid-brain did not develop the aversion despite repeated encounters with aggressive rodents. The study will be published in the Feb. 10 issue of the journal Science.

"It's very exciting because we are slowly but surely identifying mechanisms in the brain underlying psychiatric disorders that have a social withdrawal component, such as social phobia, depression and post-traumatic stress disorder, and that will allow us to find better ways to treat these disorders," Bolanos said. "This study is significant because it gives us an animal model of the disorder and opens up new areas of study."

In the experiment, the researchers subjected mice to daily bouts of social threats and subordination by aggressive rodents and continuous sensory contact with the aggressors for 10 days. Afterward, the defeated mice avoided any social contact by spending most of their time in the corner of their cages opposite other mice, including those that had not been aggressive toward them.

The defeated mice also displayed little interest in sexual interaction and showed decreased preference for palatable sugary drinks over plain water. A month later, the rodents' interest in sex and sweets had returned, but the social avoidance remained.

The researchers found that long-term use of antidepressants, such as fluoxetine (Prozac) and imipramine (Trofanil), were successful in reversing the social withdrawal in the se mice. But the successful use of the gene therapy approach to block the expression of the BDNF gene in a highly localized area of the brain suggests the potential for the development of new drug therapies with fewer side effects.

"We have made great progress in our understanding of how antidepressants work, but despite years of research, our knowledge of the changes that these drugs induce in the brain is rudimentary," Bolanos said. "Though available treatments for depression are generally safe and effective, they are still not ideal. It takes long-term treatment before seeing clinical benefit, and potential side effects are a serious problem. The findings of this study provide exciting new leads and point to potential strategies, such as developing drugs capable of targeting specific proteins in restricted brain areas."


'"/>

Source:Florida State University


Related biology news :

1. Beyond genes: Lipid helps cell wall protein fold into proper shape
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
4. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
5. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
6. Study Links Ebola Outbreaks To Animal Carcasses
7. Breakthrough Microarray-based Technology for the Study of Cancer
8. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
9. Study finds more than one-third of human genome regulated by RNA
10. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
11. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... -- Who risk to be deprived of its imprint ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT ... sensors using capacitive technology represent a fast growing market, ... an increase of 360% of the number of fingerprint ... sensor market between 2014 and 2017 (source : N+1 ...
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... ... 29, 2017 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... Device Summit 2017 venue and speaker lineup. The Summit will take place on June ... The Omni Parker House Hotel, which is located at 60 School Street, Boston, MA ...
(Date:3/29/2017)... 2017  Halozyme Therapeutics, Inc. (NASDAQ: HALO), a ... today announced that an Oncologic Drug Advisory Committee ... 11 to 0 that the benefit/risk of rituximab/hyaluronidase ... for patients in the proposed indications of follicular ... leukemia. The FDA action date is June 26, ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy scientists ... Today the company announced that its new round of awards are being given ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology: